imatinib mesylate has been researched along with Bone Marrow Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirano, M; Imai, Y; Imoto, S; Jimbo, K; Kawamata, T; Miyano, S; Ochi, K; Ogawa, M; Ohno, N; Shimizu, E; Takahashi, N; Tojo, A; Uchimaru, K; Yamaguchi, R; Yokoyama, K; Yokoyama, N | 1 |
| Annus, JK; Borbényi, Z; Marton, I; Nemes, A; Pósfai, É; Vecsei, L; Vörös, E | 1 |
| Arefi, M; de las Heras, N; García, JL; Giraldo, P; Gutiérrez, NC; Hermosín, L; Hernández-Rivas, JM; López-Corral, L; Megido, M; Peñarrubia, MJ; Queizán, JA; Vanegas, RJ | 1 |
| Anastasi, J; Hossain, NM; Jain, N; McConville, JF; Odenike, O; Steinmetz, JL | 1 |
| Bachanova, V; Begna, KH; Chen, D; Hanson, CA; Ketterling, RP; Viswanatha, DS | 1 |
| Amoroso, L; Calafiore, L; Castellano, A; Corrias, MV; Della Casa Alberighi, O; Dominici, C; Garaventa, A; Haupt, R; Luksch, R; Podda, M; Zanazzo, G | 1 |
1 trial(s) available for imatinib mesylate and Bone Marrow Neoplasms
| Article | Year |
|---|---|
Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Bone Marrow Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Longitudinal Studies; Male; Neoplasm Recurrence, Local; Neuroblastoma; Piperazines; Pyrimidines; RNA, Messenger; Tyrosine 3-Monooxygenase | 2013 |
5 other study(ies) available for imatinib mesylate and Bone Marrow Neoplasms
| Article | Year |
|---|---|
Different clonal dynamics of chronic myeloid leukaemia between bone marrow and the central nervous system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Neoplasms; Central Nervous System Neoplasms; Dasatinib; Drug Administration Schedule; Drug Substitution; Fatal Outcome; Female; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pyridazines; Pyrimidines; Recurrence | 2018 |
WATERSHED INFARCTION IN HYPEREOSINOPHILIC SYNDROME: A DIAGNOSTIC DILEMMA IN FIP1L1-PDGFR ALPHA-ASSOCIATED MYELOID NEOPLASM.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Marrow Neoplasms; Cardiomyopathies; Central Nervous System Diseases; Diagnosis, Differential; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Infarction; Magnetic Resonance Imaging; Male; Methylprednisolone; mRNA Cleavage and Polyadenylation Factors; Neuroprotective Agents; Piperazines; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2015 |
Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow Neoplasms; Female; Follow-Up Studies; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Incidence; Male; Middle Aged; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic; Treatment Outcome | 2012 |
A 32-year-old man with persistent cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia. Myeloid neoplasm associated with eosinophilia and platelet-derived growth factor receptor-alpha rearrangement.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Neoplasms; Cough; Dyspnea; Eosinophilia; Gene Rearrangement; Humans; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pulmonary Eosinophilia; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Steroids; Treatment Outcome | 2012 |
A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Bone Marrow Neoplasms; Gene Rearrangement; Humans; Imatinib Mesylate; Immunophenotyping; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Sarcoma; Treatment Outcome | 2013 |